UTHR · Intrinsic value
Is United Therapeutics Corporation (UTHR) overvalued or undervalued?
United Therapeutics Corporation (UTHR) trades at the delayed market price of $533.12 a share. That price already implies revenue growth of −0.5% a year for 5 years. TickerWorth's fair value is $502.46 a share (priced within our range of $252.14 – $588.23). We do not call it over- or undervalued from inside our range.
Model by Miraaj Patel · generated from SEC filings and market data · Updated Oct 19, 2026 · How these pages are made
Is UTHR fairly valued?
- Fair value
- $502.46
- Market price
- $533.12
- Downside to fair value
- 5.8%
- Verdict
- Priced within our range of $252.14 – $588.23
Reverse DCF: Today's price implies revenue growth of −0.5% a year for 5 years; our model assumes 4.0% a year on average over the same horizon.
What is UTHR's TickerWorth Score?
Scores higher than most companies we compare it with
Compared with Healthcare companies in US
Its strongest point: a profitable, high-quality business. Its weakest: growth is slow or negative.
- Value · 58 of 100
Cheaper than 58% of Healthcare companies in US
- Price vs worth · 45 of 100
- Quality · 90 of 100
More profitable than 90% of Healthcare companies in US
- Financial health · 87 of 100
Financially stronger than 87% of Healthcare companies in US
- Growth · 25 of 100
Growing faster than 25% of Healthcare companies in US
- Momentum · 54 of 100
Outperformed 54% of Healthcare companies in US over the past year
Confidence: High confidence · Scored
Get the Undervalued Company of the Week.
UTHR DCF valuation, input by input
TickerWorth's fair value for United Therapeutics Corporation (UTHR) is $502.46 a share, against the delayed market price of $533.12 (priced within our range of $252.14 – $588.23). We do not call it over- or undervalued from inside our range. It is a model estimate, and every input behind it is sourced below. This is an educational model, not a price target or a recommendation.
Read the full reasoning
One of the lenses behind that blended figure is a discounted-cash-flow model, which on its own values UTHR at about $588.23 per share. The rest of this page walks through that DCF — its assumptions, reverse-DCF and discount-rate sensitivity — because it is the auditable anchor of the blend.
The valuation discounts United Therapeutics Corporation's projected free cash flows at a weighted-average cost of capital (WACC) of 7.4%, with a long-run terminal growth rate of 2.5%. About 80% of the enterprise value comes from the terminal value — the portion beyond the explicit forecast window — which is typical for a stable, cash-generative business and a reminder that small changes in the discount rate or terminal growth assumption swing the intrinsic value meaningfully.
Running the DCF in reverse — solving for the growth the current price already assumes — the market is implying roughly -0.5% annual revenue growth for UTHR. Our base case instead compounds to about 4.0% a year over the same forecast, so the market is pricing in slower growth than our base case. The reverse-DCF is a quick sanity check: it reframes 'is this stock cheap?' as 'do I believe the growth the price requires?' rather than arguing over a single point estimate of fair value.
Sensitivity matters more than any single number. Across a reasonable band of discount-rate assumptions, UTHR's modeled DCF value ranges from about $419.35 to $1,105 per share. If that range still sits below today's price, the market is optimistic relative to the model across the whole band; if it brackets the price, the stock is roughly fairly valued on our assumptions. Use the interactive slider to see exactly where your own cost-of-capital view lands.
How to read this page: the DCF fair value is what United Therapeutics Corporation would be worth if its cash flows grow as modeled and are discounted at the stated WACC. The assumptions table shows every input and its source; the reverse-DCF shows what the market believes; the sensitivity band shows how fragile the answer is. None of this is investment advice — it is a transparent, auditable framework for forming your own view of UTHR's intrinsic value. Figures update as new filings and prices come in.
Every input behind UTHR's DCF
| Input | Value |
|---|---|
| Base-year revenueUnited Therapeutics Corporation FY2025 10-K (accession 0001082554-26-000006): us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, FY2025 full year. | $3,182,700,000 |
| Base EBIT marginUnited Therapeutics Corporation FY2025 10-K (accession 0001082554-26-000006): us-gaap:OperatingIncomeLoss 1,492,500,000 / revenue 3,182,700,000 = 46.89%, FY2025. | 46.9% |
| Forecast revenue growthESTIMATEAssumption — TickerWorth's 5-year explicit forecast | 4% → 4% → 4% → 4% → 4% |
| Risk-free rateLive feed — US 10-year Treasury yield (^TNX) | 4.8% |
| BetaLive feed — yfinance, 5-year monthly beta vs the S&P 500 (clamped to 0.4–2.5) | 0.56 |
| Terminal growthESTIMATEAssumption — TickerWorth house default 2.5%, held below WACC | 2.5% |
| Diluted sharesUnited Therapeutics Corporation FY2025 10-K (accession 0001082554-26-000006): WeightedAverageNumberOfDilutedSharesOutstanding = 47,900,000 shares, FY2025. | 48M |
| Market priceBackup price feed · as of 2026-10-19 13:19 UTC | $533.12 |
Change UTHR's assumptions
The discount-rate dial and the editable model
ProChange growth, margin and WACC yourself — Pro (7-day free trial, card required).
What does United Therapeutics Corporation do?
What does it do?
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It operates in the Drug Manufacturers - Specialty & Generic industry (Healthcare sector), headquartered in United States. The company employs roughly 1,400 people.
How does it make money?
The business turns $3.2B in annual revenue into profit. Out of every $100 of sales, about $42 is left as operating profit (operating margin of 42.2%), after a 86% gross margin on the products/services it sells. After all costs, taxes and interest, 41.6% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks solid: comfortably covers its short-term bills (5.7× current ratio), and is currently profitable.
Who at UTHR filed insider trades?
| Date | Insider | Relationship | What happened | Value | Filing |
|---|---|---|---|---|---|
| ROTHBLATT MARTINE A | Director, Chairperson & CEO | Option exercise | $1,118,720.00 | Form 4 for ROTHBLATT MARTINE A (opens sec.gov in a new tab) | |
| ROTHBLATT MARTINE A | Director, Chairperson & CEO | Open-market sale | $151,873.87 | Form 4 for ROTHBLATT MARTINE A (opens sec.gov in a new tab) | |
| ROTHBLATT MARTINE A | Director, Chairperson & CEO | Open-market sale | $629,864.40 | Form 4 for ROTHBLATT MARTINE A (opens sec.gov in a new tab) | |
| ROTHBLATT MARTINE A | Director, Chairperson & CEO | Open-market sale | $247,461.76 | Form 4 for ROTHBLATT MARTINE A (opens sec.gov in a new tab) | |
| ROTHBLATT MARTINE A | Director, Chairperson & CEO | Open-market sale | $201,598.77 | Form 4 for ROTHBLATT MARTINE A (opens sec.gov in a new tab) | |
| ROTHBLATT MARTINE A | Director, Chairperson & CEO | Open-market sale | $146,538.77 | Form 4 for ROTHBLATT MARTINE A (opens sec.gov in a new tab) |
A disclosure, not a signal to trade. Source: SEC EDGAR (Form 4). Older filings and the 90-day buying-and-selling read are part of Pro. See plans
Common questions
What is UTHR's intrinsic value?
TickerWorth's blended fair value for United Therapeutics Corporation (UTHR) is $502.46 per share, versus a market price of $533.12 (priced within our range of $252.14 – $588.23).
Is UTHR overvalued or undervalued?
Priced within our range of $252.14 – $588.23 at $533.12. We don't call UTHR overvalued or undervalued from a range. This is an educational estimate, not advice.
What discount rate is used for UTHR?
A WACC of 7.4% and a terminal growth rate of 2.5%.
Is United Therapeutics stock undervalued?
TickerWorth's fair value for United Therapeutics Corporation (UTHR) is $502.46 against a market price of $533.12. Our read: Priced within our range of $252.14 – $588.23. This is a model estimate, not investment advice.
United Therapeutics (UTHR) DCF valuation and fair value
Our fair value for United Therapeutics Corporation (UTHR) is $502.46, built on a 7.4% discount rate (WACC) and 2.5% terminal growth. It blends our discounted-cash-flow model with other valuation lenses. Every assumption is listed on this page with its source.
What growth is priced into United Therapeutics stock?
Today's price implies revenue growth of −0.5% a year for 5 years; our model assumes 4.0% a year on average over the same horizon. This is a reverse DCF: it holds our cash-flow model's other inputs and solves for the revenue growth that makes the model equal today's price of $533.12. A model estimate, not investment advice.
United Therapeutics (UTHR) insider trading
The most recent insider filing (SEC Form 4) for United Therapeutics Corporation (UTHR): ROTHBLATT MARTINE A, Director, Chairperson & CEO, option exercise on 2026-10-15. The latest filings are listed on this page. A disclosure, not a signal to trade.
Not investment advice. TickerWorth Score is a model output.
Educational tool. Every output reflects the assumptions shown — not a prediction and not investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public filings and market data that can be wrong.